Article
Whole-genome analysis informs breast cancer response to aromatase inhibition.
Nature - 10 Jun 2012
Ellis Matthew J, Ding Li, Shen Dong, Luo Jingqin, Suman Vera J, Wallis John W, Van Tine Brian A, Hoog Jeremy, Goiffon Reece J, Goldstein Theodore C, Ng Sam, Lin Li, Crowder Robert, Snider Jacqueline, Ballman Karla, Weber Jason, Chen Ken, Koboldt Daniel C, Kandoth Cyriac, Schierding William S, McMichael Joshua F, Miller Christopher A, Lu Charles, Harris Christopher C, McLellan Michael D, Wendl Michael C, DeSchryver Katherine, Allred D Craig, Esserman Laura, Unzeitig Gary, Margenthaler Julie, Babiera G V, Marcom P Kelly, Guenther J M, Leitch Marilyn, Hunt Kelly, Olson John, Tao Yu, Maher Christopher A, Fulton Lucinda L, Fulton Robert S, Harrison Michelle, Oberkfell Ben, Du Feiyu, Demeter Ryan, Vickery Tammi L, Elhammali Adnan, Piwnica-Worms Helen, McDonald Sandra, Watson Mark, Dooling David J, Ota David, Chang Li-Wei, Bose Ron, Ley Timothy J, Piwnica-Worms David, Stuart Joshua M, Wilson Richard K, Mardis Elaine R
Abstract excerpt
To correlate the variable clinical features of oestrogen-receptor-positive breast cancer with somatic alterations, we studied pretreatment tumour biopsies accrued from patients in two studies of neoadjuvant aromatase inhibitor therapy by massively parallel sequencing and analysis. Eighteen significantly mutated genes were identified, including five genes (RUNX1, CBFB, MYH9, MLL3 and SF3B1) previously linked to...
Read the complete abstract on PubMed